Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 12, 2010, Pages 1256-1265

  Kirmizis, Dimitrios ^a   Papagianni, Aikaterini ^a   Dogrammatzi, Fani ^b   Skoura, Lemonia ^b   Belechri, Anna Maria ^a   Alexopoulos, Efstathios ^a   Efstratiadis, Georgios ^a   Memmos, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University Medical School   (Greece)

Author keywords

References

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD64 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIGEN; FAS LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; L SELECTIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MALE; MONOCYTE; OXIDATIVE STRESS;

EID: 78650946597     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.5710     Document Type: Article

References (31)

1. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Bele-chri AM, Alexopoulos E, Memmos D: Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic hemodialysis patients. Nephrol Dial Transplant, 2003; 18: 113-119
2. Takemoto M, Liao JK: Pleiotropic effects of 3-Hydroxy-3-Methylglutaryl coenzyme A reductase inhibitors. Arte-rioscler Thromb Vasc Biol, 2001; 21: 1712-1719
3. Palinski W, Tsimikas S: Immunomodulatory Effects of Statins: Mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol, 2002; 13: 1673-1681
4. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet, 1996; 348: 1079-1082
5. Kirmizis D, Chatzidimitriou D: Pleiotropic vasoprotec-tive effects of statins: The chicken or the egg? Drug Des Devel Ther, 2009; 3: 191-204
6. Palinski W, Napoli C: Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol, 2002; 22: 1745-1750
7. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J: Anti-inflammatory and immunomodulatory effects of statins. Kidney Int, 2003; 63: 12-23
8. Rothe G, Gabriel H, Kovacs E, Klucken J, Stöhr J, Kin-dermann W, Schmitz G: Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hyper-cholesterolemia. Arterioscler Thromb Vasc Biol, 1996; 16: 1437-1447
9. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of Pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1999; 100: 230-235
10. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 2001; 286: 64-70
11. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F: Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes. New evidence for direct anti-inflammatory effects of statins. ArteriosclerThromb Vase Biol, 2005; 25: 1231-1236
12. Mayer C, Gruber HJ, Landl EM, Pailer S, Scharnagl H, Truschnig-Wilders M, März W: Rosuvastatin reduces in-terleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther, 2007; 45: 319-327
13. Jialal I, Devaraj S, Singh U: Sources of CRP in atherosclerotic lesions. Am J Pathol, 2006; 168: 1054-1055
14. März W, Winkler K, Nauck M, Böhm BO, Winkelmann BR: Effects of statins on C-reactive protein and interleu-kin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol, 2003; 92: 305-308
15. Censer B, Crammer TB, Stojakovic T, Siekmeier R, März W: Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and metaanalysis. Int J Clin Pharmacol Ther, 2008; 46: 497-510
16. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, Treusch A, Morcos M, Weiss T, Borcea V, Abdel Khalek AK, Amiral J, Tritschler H, Ritz E, Wahl P, Ziegler R, Bierhaus A, Nawroth PP: Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxida-tive-stress sensitive transcription factor NF-/cB. Diabeto-logia, 1999; 42: 222-232
17. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, Ramires JA, Serrano CV Jr: Atorvas-tatin reduces proinflammatory markers in hypercholester-olemic patients. Atherosclerosis, 2004; 177: 161-166
18. Ziegler-Heitbrock HWL, Ulevitch RJ: CD14: Cell surface receptor and differentiation marker. Immunol Today, 1993; 14: 121-125
19. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD: Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature, 1998; 392: 505-509
20. Serrano CV Jr, Yoshida VM, Venturinelli ML, D'Amico E, Monteiro HP, Ramires JA, da Luz PL: Effect of simvas-tatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis, 2001; 157: 505-512
21. Adam O, Laufs U: Antioxidant effects of statins. Arch Toxicol, 2008; 82: 885-892
22. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, März W, Drexler H: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation, 2005; 111: 2356-2363
23. Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S: Atorvas-tatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels, 2008; 23: 249-256
24. Riccioni G, Bazzano LA, Bucciarelli T, Mancini B, di Ilio E, D'Orazio N: Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study. Expert Opin Pharmacother, 2008 Oct; 9(14): 2403-2408
25. Fassett RG, Robertson IK, Ball MJ, Geraghty D P, Shar-man JE, Coombes JS: Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J Atheroscler Thromb, 2010 Mar 31; 17(3): 235-241
26. Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K: Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl co-enzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb, 2009 Oct; 16(5): 539-545
27. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med, 2005; 353: 238-248 [Erratum, N Engl J Med, 2005; 353: 1640]
28. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich R P, Gottlow M, Johns-son E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodi-alysis. N Engl J Med, 2009; 360 (14): 1395-1407
29. Ridker PM, MacFadyen J, Cressman M, Glynn RJ: Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-re-active protein. J Am Coll Cardiol, 2010; 55: 1266-1273
30. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggio-ni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med, 2004; 351: 1285-1295
31. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfef-fer M; Cholesterol and Recurrent Events (CARE) Trial Investigators: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ, 2006; 332: 1426